BioNTech SE (BNTX) |
|
128.2 -1.19 (-0.92%)
|
03-24 16:00 |
|
Open: |
128.5 |
Pre. Close: |
129.39 |
|
High:
|
129.39 |
Low:
|
127.23 |
|
Volume:
|
617,104 |
Market Cap:
|
31,112(M) |
|
|
|
Technical analysis |
as of: 2023-03-24 4:24:30 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 158.03  One year: 165.76 |
| Support: |
Support1: 124.58 Support2: 103.65 |
| Resistance: |
Resistance1: 135.3 Resistance2: 141.92 |
| Pivot: |
130.16 |
| Moving Average: |
MA(5): 131.33 MA(20): 129.98
MA(100): 149.04 MA(250): 149.92 |
| MACD: |
MACD(12,26): -2.1 Signal(9): -2.7  |
| Stochastic oscillator: |
%K(14,3): 47.3 %D(3): 66.1 |
| RSI: |
RSI(14): 39.3 |
| 52-week: |
High: 188.98 Low: 117.08 |
| Average Vol(K): |
3-Month: 671 (K) 10-Days: 576 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ BNTX ] has closed above bottom band by 24.2%. Bollinger Bands are 66.5% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 10 bars. This is a sign that the market may be about to initiate a new trend. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
129.52 - 130.23 |
130.23 - 130.82 |
|
Low:
|
125.5 - 126.39 |
126.39 - 127.13 |
|
Close:
|
126.85 - 128.22 |
128.22 - 129.35 |
|
Company Description |
|
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany. |
Headline News |
Mon, 27 Mar 2023
Research Analysts Issue Forecasts for BioNTech SE's FY2022 ... - MarketBeat
Tue, 21 Mar 2023
BioNTech SE (NASDAQ:BNTX) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Simply Wall St
Tue, 21 Mar 2023
Sarepta Therapeutics (SRPT) Soars 7.1%: Is Further Upside Left in ... - Nasdaq
Mon, 20 Mar 2023
BioNTech SE Sponsored ADR (BNTX) Outpaces Stock Market Gains ... - Nasdaq
Mon, 20 Mar 2023
BioNTech licenses solid tumor candidate from OncoC4 (NASDAQ ... - Seeking Alpha
Wed, 15 Mar 2023
FDA Approves Pfizer/BioNTech's Bivalent COVID-19 Vaccine For Youngest Kids - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Outperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
243 (M) |
| Shares Float |
90 (M) |
|
% Held by Insiders
|
64 (%) |
|
% Held by Institutions
|
18.1 (%) |
|
Shares Short
|
1,960 (K) |
|
Shares Short P.Month
|
1,940 (K) |
Stock Financials |
|
EPS
|
41.95 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
76.44 |
|
Profit Margin (%)
|
55.5 |
|
Operating Margin (%)
|
68 |
|
Return on Assets (ttm)
|
42.8 |
|
Return on Equity (ttm)
|
76.2 |
|
Qtrly Rev. Growth
|
-43.1 |
|
Gross Profit (p.s.)
|
66.21 |
|
Sales Per Share
|
76.47 |
|
EBITDA (p.s.)
|
52.45 |
|
Qtrly Earnings Growth
|
-43.5 |
|
Operating Cash Flow
|
12,550 (M) |
|
Levered Free Cash Flow
|
10,200 (M) |
Stock Valuations |
|
PE Ratio
|
3.05 |
|
PEG Ratio
|
-0.1 |
|
Price to Book value
|
1.67 |
|
Price to Sales
|
1.67 |
|
Price to Cash Flow
|
2.47 |
Stock Dividends |
|
Dividend
|
2.1 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
1.6% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
